Bosh sahifa500124 • BOM
add
Dr Reddy's Laboratories Ltd
Yopilish kursi
1 194,55 ₹
Kunlik diapazon
1 194,00 ₹ - 1 222,85 ₹
Yillik diapazon
1 074,35 ₹ - 1 420,20 ₹
Bozor kapitalizatsiyasi
1,01 trln INR
Oʻrtacha hajm
59,31 ming
Narx/foyda
18,98
Dividend daromadliligi
0,66%
Asosiy maydon
NSE
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(INR) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Daromad | 80,16 mlrd | 16,51% |
Joriy xarajat | 29,72 mlrd | 24,54% |
Sof foyda | 12,55 mlrd | -15,18% |
Sof foyda marjasi | 15,66 | -27,20% |
Har bir ulushga tushum | 15,83 | -11,13% |
EBITDA | 22,02 mlrd | 8,53% |
Amaldagi soliq stavkasi | 30,01% | — |
Balans
Jami aktivlari
Jami passivlari
(INR) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Naqd pul va qisqa investitsiyalar | 63,07 mlrd | -7,15% |
Jami aktivlari | 465,96 mlrd | 34,27% |
Jami passivlari | 156,67 mlrd | 66,79% |
Umumiy kapital | 309,28 mlrd | — |
Tarqatilgan aksiyalar | 833,05 mln | — |
Narxi/balansdagi bahosi | 3,26 | — |
Aktivlardan daromad | 10,24% | — |
Kapitaldan daromad | 13,21% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
(INR) | sen, 2024info | Y/Y qiyosi |
---|---|---|
Sof foyda | 12,55 mlrd | -15,18% |
Operatsiyalardan naqd pul | 9,32 mlrd | -48,03% |
Sarmoyadan naqd pul | -19,07 mlrd | -322,21% |
Moliyadan naqd pul | 16,15 mlrd | 329,53% |
Naqd pulning sof oʻzgarishi | 6,37 mlrd | 1,03% |
Boʻsh pul | 3,92 mlrd | -72,47% |
Haqida
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Tashkil etilgan
1984
Bosh ofis
Sayt
Xodimlar soni
27 048